Is there something other than imatinib mesilate in therapeutic options for GIST?

A phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST)

(2017) H. Dumez et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III trial of nilotinib in patients with advanced gastrointestinal stromal tumor (GIST): First results from ENEST g3.

(2017) P. Reichardt et al.   JOURNAL OF CLINICAL ONCOLOGY

Time to secondary resistance (TSR) after interruption of imatinib (IM) in advanced GIST: Updated results of the prospective French Sarcoma Group randomized phase III trial on long-term survival.

(2017) A. Le Cesne et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study.

(2017) M. Ryu et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study of dasatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).

(2017) J. C. Trent et al.   JOURNAL OF CLINICAL ONCOLOGY

Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): Final results of a University of Chicago Phase II Consortium trial.

(2017) H. L. Kindler et al.   JOURNAL OF CLINICAL ONCOLOGY

Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study

(2011) H Joensuu et al.   BRITISH JOURNAL OF CANCER

Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor

(2011) Akira Sawaki et al.   CANCER

Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor

(2011) J. Li et al.   EJSO

Protocol Information Provides Opportunity for Patient Safety and Quality Improvement

(2011) Thomas J. George et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors

(2010) Robert S. Benjamin et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A decade of tyrosine kinase inhibitor therapy: Historical and current perspectives on targeted therapy for GIST

(2010) Jean-Yves Blay   CANCER TREATMENT REVIEWS

Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST)

(2010) Axel Le Cesne et al.   EUROPEAN JOURNAL OF CANCER

Gastrointestinal stromal tumor: a bridge between bench and bedside

(2010) Toshirou Nishida et al.   Gastric Cancer

Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review

(2010) Munira Essat et al.   INTERNATIONAL JOURNAL OF CANCER

Increasing Mastectomy Rates for Early-Stage Breast Cancer? Population-Based Trends From California

(2010) Scarlett Lin Gomez et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of Two Doses of Imatinib for the Treatment of Unresectable or Metastatic Gastrointestinal Stromal Tumors: A Meta-Analysis of 1,640 Patients

(2010)   JOURNAL OF CLINICAL ONCOLOGY

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

(2010) Axel Le Cesne et al.   LANCET ONCOLOGY

Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate

(2009) Akira Sawaki et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A Phase I Study of Single-Agent Nilotinib or in Combination with Imatinib in Patients with Imatinib-Resistant Gastrointestinal Stromal Tumors

(2009) G. D. Demetri et al.   CLINICAL CANCER RESEARCH

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers

(2009) J.C. Soria et al.   EUROPEAN JOURNAL OF CANCER

Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib

(2009) M. Montemurro et al.   EUROPEAN JOURNAL OF CANCER

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial

(2009) Ronald P DeMatteo et al.   LANCET

Secondary mutations in the kinase domain of the KIT gene are predominant in imatinib-resistant gastrointestinal stromal tumor

(2008) Toshirou Nishida et al.   CANCER SCIENCE

Clinical significance of oncogenicKITandPDGFRAmutations in gastrointestinal stromal tumours

(2008) J Lasota et al.   HISTOPATHOLOGY

Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202)

(2008) Toshirou Nishida et al.   International Journal of Clinical Oncology

Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group

(2008) Michael C. Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor

(2008) Michael C. Heinrich et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033

(2008) Charles D. Blanke et al.   JOURNAL OF CLINICAL ONCOLOGY